Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $30M
Founded date: 2003
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Hercules C... | htgc.com |
| - | Bessemer V... | bvp.com |
| - | Lightstone... | lightstone... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.12.2011 | - | $30M | - |
Mentions in press and media 21
| Date | Title | Description |
| 19.03.2026 | Bambusa Therapeutics Appoints Todd James Chief Financial Officer | - Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its $11.5 b... |
| 01.10.2021 | Why the autopsy of Zoom’s dead $14.7 billion deal matters | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s been a busy 24 hours, so let’s run through the news. Paid Content How to ensure your markete... |
| 01.10.2021 | Why the autopsy of Zoom’s dead $14.7 billion deal matters | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s been a busy 24 hours, so let’s run through the news. Paid Content How businesses can create ... |
| 30.09.2021 | Merck to buy Acceleron Pharma in deal valued at $11.5 billion | Merck & Co. agreed to buy Acceleron Pharma Inc. in a deal valuing the drugmaker at $11.5 billion, building out its portfolio of therapies to treat cancer and rare diseases. Acceleron shareholders will get $180 a share in cash, the compa... |
| 18.06.2021 | ACCELERON PHARMA INC. Acceleron Pharma : Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval (Fo... | Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 6... |
| 29.03.2019 | bluebird’s gene therapy gets nod from EMA panel – for real this time | Shares of bluebird on the Nasdaq opened up about 2 percent following the news. SVB Leerink analyst Mani Foroohar wrote in a note to clients Friday that final approval is expected, forecasting that peak global sales in TDT could reach $1.2 b... |
| 20.03.2019 | Flagship Pioneering raises $824M in new fund | “With each year of company origination, as we honed our pioneering approach, we have steadily increased our capacity to launch transformative ventures,” said Flagship CEO Noubar Afeyan, in a statement. “Our new fund will complement our orig... |
| 03.01.2018 | A better approach to growth factors? Scholar Rock raises $47M on SMA promise | Scholar Rock, a biotech based of out Cambridge, MA, just got a $47 million infusion of cash to develop what the company considers smarter, next-generation growth factor drugs. Their approach involves more targeted tweaki... |
| 26.03.2015 | Flagship Ventures raises $537M in new fund; plans to launch 5 companies per year | The company’s previous fund was $269 million. Some of its more successful exits during this biotech boom have been the IPOs of Receptos, Agios Pharmaceuticals, Tetraphase Pharmaceuticals and Acceleron Pharma. Other notable companies that re... |
| 26.03.2014 | The 2014 Midas List: Fewer New Names And More Explosive Exits | For the third straight year, the number of newcomers to the Midas List has dropped. From 38 new names in 2012 to 25 new names in 2013, the number of entrants to this year’s List dipped even further, to 19. The data from previous years’ Mida... |
Show more